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Background: Altered immune function during ageing results in increased production of nitric oxide (NO) and other
inflammatory mediators. Recently, we have reported that NO production was inhibited by naturally-occurring
proteasome inhibitors (quercetin, δ-tocotrienol, and riboflavin) in lipopolysaccharide (LPS)-stimulated RAW 264.7
cells, and thioglycolate-elicited peritoneal macrophages from C57BL/6 mice. In a continuous effort to find more
potent, non-toxic, commercially available, naturally-occurring proteasome inhibitors that suppress inflammation, the
present study was carried out to describe the inhibition of NF-κB activation and NO, TNF-α, IL-6, IL-1β, and iNOS
expression by trans-resveratrol, trans-pterostilbene, morin hydrate, and nicotinic acid in LPS-induced RAW 264.7 cells
and thioglycolate-elicited peritoneal macrophages from C57BL/6 and BALB/c mice.
Results: The present results indicate that resveratrol, pterostilbene, and morin hydrate caused significant inhibition
(>70% to 90%; P< 0.02) in the activities of chymotrypsin-like, trypsin-like, and post-acidic (post-glutamase)
proteasome sites in RAW 264.7 cells at a dose of only 20 μM. These compounds also inhibited the production of
NO by RAW-264.7 cells stimulated with LPS alone (>40%; P< 0.05), or LPS + interferon-γ (IFN-γ; >60%; P< 0.02).
Furthermore, resveratrol, pterostilbene, morin hydrate, and quercetin suppressed secretion of TNF-α (>40%;
P< 0.05) in LPS-stimulated RAW 264.7 cells, and suppressed NF-κB activation (22% to 45%; P< 0.05) in
LPS-stimulated HEK293T cells. These compounds also significantly suppressed LPS-induced expression of TNF-α,
IL-1β, IL-6, and iNOS genes in RAW 264.7 cells, and also in thioglycolate-elicited peritoneal macrophages from
C57BL/6 and BALB/c mice.
Conclusions: The present results clearly demonstrate that resveratrol and pterostilbene are particularly potent
proteasome inhibitors that suppress expression of genes, and production of inflammatory products in LPS-stimulated
RAW 264.7 cells, and macrophages from C57BL/6 and BALB/c mice. Resveratrol and pterostilbene which are present in
grapes, blueberries, and red wine, have been implicated as contributing factors to the lower incidence of
cardiovascular disease in the French population, despite their relatively high dietary fat intake. Consequently, it appears
likely that the beneficial nutritional effects of resveratrol and pterostilbene are due at least in part, to their ability to
inhibit NF-κB activation by the proteasome, thereby suppressing activation of
pro-inflammatory cytokines and iNOS genes, resulting in decreased secretion of TNF-α, IL-1β, IL-6, and NO, in response
to inflammatory stimuli. This is the first report demonstrating that resveratrol and pterostilbene act as proteasome
inhibitors, thus providing a mechanism for their anti-inflammatory effects.
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Alterations in normal regulation of immune function
occur during the ageing process, as well as in a variety
of pathologic human conditions [1-3]. We have been
particularly interested in dysregulation of immune func-
tion associated with ageing, as manifested by enhanced
nitric oxide (NO) production by macrophages from sen-
escent mice [4], and the potential impact of reversing
these age-associated alterations in immune regulation.
Toward this end, we reported that several naturally-
occurring proteasome inhibitors (e.g. quercetin, δ-
tocotrienol, riboflavin) inhibit production of inducible
nitric oxide synthase (iNOS), nitric oxide (NO) and
tumor necrosis factor-alpha (TNF-α) by lipopolysacchar-
ide (LPS)-stimulated RAW 264.7 cells and murine
macrophages in vitro, and that dietary supplementation
with these compounds has comparable suppressive
effects on the secretion of TNF-α and production of NO
in vivo and ex vivo [5,6]. Our research has focused pri-
marily on macrophages because they are highly sensitive to
LPS stimulation and respond by producing TNF-α,
interleukin-1β (IL-1β), IL-6, IL-8, NO, NF-κB, and activator
protein-1 (AP-1), which are largely responsible for many of
the pathophysiological events associated with gram-
negative sepsis and other inflammatory diseases [5-7].
The present study was carried out to identify additional
non-toxic, commercially available, naturally-occurring pro-
teasome inhibitors with potent anti-inflammatory proper-
ties. After initially screening a large number of compounds
for their effect on proteasome protease activities, we opted
to study trans-resveratrol, trans-pterostilbene, morin hy-
drate, and nicotinic acid (niacin; vitamin B3), more thor-
oughly; quercetin was included as a positive control,
because we have carefully characterized this compound in
previous publications [5-7]. Resveratrol, pterostilbene,
morin hydrate, nicotinic acid (niacin) and quercetin are
commonly found in nature, and have antioxidant, free-
radical scavenging, anti-inflammatory, and hypolipidemic
properties [8-13]. Pterostilbene is a methoxy ester of meta-
phenolic (hydroxyl) groups of resveratrol, and morin hy-
drate contains meta-hydroxy groups compared to ortho-
hydroxy groups present in quercetin (Figure 1). The posi-
tive physiological effects of resveratrol, pterostilbene, morin
hydrate, nicotinic acid (niacin; vitamin B3), and quercetin
have been reported in the literature and these agents have
been approved by the FDA for human consumption for
many years [8-14]. Resveratrol, pterostilbene and quercetin
are active components in grapes, blueberries and red wine,
contributing to the lower incidence of cardiovascular dis-
ease in the French population [8,9], and morin hydrate (iso-
flavonoid found in tea leaves) has been shown to be an
effective hypocholesterolemic agent [12].
We carried out the present investigation to specifically
demonstrate the relative capacity of these compounds(trans-resveratrol, trans-pterostilbene, morin hydrate,
nicotinic acid, and quercetin) to inhibit key proteasomal
enzymatic activities (e.g. chymotrypsin-like, trypsin-like,
and post-glutamase activity), and production of NO, the
iNOS enzyme, and certain pro-inflammatory cytokines
(TNF-α, IL-1β, and IL-6). In order to make sure that the
effectiveness of these compounds remains uniform and
consistently reproducible their anti-inflammatory prop-
erties were examined in LPS-stimulated RAW 264.7
cells and in thioglycolate-elicited peritoneal macro-




Highly purified, deep rough chemotype LPS (Re-LPS)
from E. coli D31m4 was prepared as described [15]. Dul-
becco’s Modified Eagle Medium (DMEM) heat-
inactivated low-endotoxin fetal bovine serum (FBS) and
gentamicin were purchased from Cambrex (Walkersville,
MD, USA) for tissue culture studies. Proteasome-Glo
reagents and luciferase assay system for determining the
proteasomal activities were purchased from Promega
(Madison, WI, USA). Thioglycolate was purchased from
Sigma, Aldrich Chemical Co. (St. Louis, MO, USA) and
RNeasy mini kit from QIAGEN Sciences (Germantown,
MD, USA). The murine macrophage cell line, RAW
264.7 cells (ATCC #. TIB-71) was purchased from
American Type Culture Collection (Manassas, VA,
USA), and HEK293T cells (ATCC #. CRL-11268; human
embryonic kidney cells) was purchased from American
Type Culture Collection (Rockville, MD, USA). trans-
Resveratrol was purchased from “Mega Resveratrol” (60
Newtown Toad # 32, Danbury CT, USA), trans-pterostil-
bene from Shanxi Yong Yuan, Biotechnology Co, Ltd.
(China), and nicotinic acid (niacin, vitamin B3) from
VOIGT Global Distribution Inc. (P.O.Box. 1130,
Lawrence, Kansas, USA). (−) Riboflavin and morin hy-
drate were purchased from Sigma-Aldrich Chemical Co
(St. Louis, MO, USA). Quercetin was purchased from
Alfa Aesar (Johnson Matthey Co. Lancastor, UK). Super-
Fect transfection reagent (Flag-TLR4 wild type +
pELAM-luciferase {NF-κB reporter} + β-gal reporter
plasmids +MD-2 +CD14 constructs) was purchased
from QIAGEN, Valencia, CA, USA. Luciferase assay lysis
buffer, and Luciferase assay system were obtained from
Promega, Madison, WI, USA. β-Galactosidase was pur-
chased from Tropix; Galacto Light System from Bedford,
MA, USA. Berthold LB 9507 Luminometer was pur-
chased from Berthold Technologies, Oak Ridge, TN,
USA, and Stratagene staining kit from Stratagene, La
Jolla, CA, USA. The 50% δ-tocotrienol fraction from
annatto seeds was purchased from American River (Boston,
MA, USA), and purified from that fraction by flash
Figure 1 Chemical structures of various compounds used in this study.
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δ-tocotrienol was established by high pressure liquid chro-
matography (HPLC) against its standard as reported earlier
[7]. trans-Resveratrol and trans-pterostilbene will be re-
ferred to as resveratrol and pterostilbene, respectively,
throughout this manuscript.
Animals
6-week-old female, C57BL/6, Wild Type (WT) and
BALB/c mice were obtained from the Jackson Labora-
tory (Bar Harbor, ME, USA). Mice used in this study
received humane care in compliance with the principles
of laboratory animal care formulated by the National So-
ciety of Health Guide for the “Care and Use of Labora-
tory Animals” by the US National Society of Health
(NIH Publication No 85–23, revised 1996). The experi-
mental procedures involving animals were reviewed and
approved by the “Institutional Animal Care and Use Com-
mittee of UMKC”, Medical School, MO. All 6-week-old
mice were acclimatized to the new environment for14 days before beginning experimentation. Mice were fed
ad libitum regular commercial mouse diet and had free
access to water throughout the experiment. A 12 h light
and 12 h dark cycle was maintained throughout the study.
Cell culture and maintenance
RAW 264.7 cells or thioglycolate-elicited peritoneal
macrophages derived from 8-week-old C57BL/6 or
BALB/c mice were cultured in DMEM supplemented
with 10% heat inactivated FBS and 10 mg/mL gentami-
cin at 37°C in a humidified, 5% CO2/95% air atmosphere
as described previously [5,16,17].
Effects of resveratrol, pterostilbene, morin hydrate,
nicotinic acid, and quercetin on proteasomal
chymotrypsin-like, trypsin-like, and post-glutamase
enzymatic activities in RAW 264.7 whole cells
The comparative inhibitory effects of resveratrol, pteros-
tilbene, morin hydrate, nicotinic acid, and quercetin on
the chymotrypsin-like, trypsin-like, and post-glutamase
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cells were carried out essentially as reported recently [5].
Briefly RAW 264.7 cells (1x104 cells/well) were allowed
to adhere to wells in white plates (96-well, Fisher,
0877126) for 2 h, followed by the addition of various
concentrations of resveratrol, pterostilbene, morin hy-
drate, nicotinic acid, or quercetin [10, 20, 40, 80, 160, or
320 μM in 100 μL; dissolved in 0.2% dimethyl sulfoxide
(DMSO)]. The mixtures were incubated at 37°C in an in-
cubator in a 5% CO2/95% air atmosphere, for 60 min,
and allowed to equilibrate to room temperature for 20
minutes before adding the Proteasome-Glo reagent (Pro-
mega, Madison, WI, USA). Proteasome-Glo reagent (100
μL) was added to each well to a total volume of 200 μL/
well (tris buffer, pH 7.5; 0.02 M). The plates were cov-
ered with a plate sealer and kept in the dark at room
temperature for 30 min. The relative luminescence units
(RLU) of assays were read in a Promega Plate Lumin-
ometer. The chymotrypsin-like, trypsin-like, or post-
glutamase activities were quantified by measuring lumi-
nescence after treatment of RAW 264.7 whole cells with
various concentrations of each compound in a Lumin-
ometer (Promega, Madison, WI, USA), according to the
manufacturer’s directions.
Effects of resveratrol, pterostilbene, morin hydrate,
nicotinic acid (niacin), and quercetin on the production of
nitric oxide (NO) by RAW 264.7 cells stimulated with
medium only, LPS, or LPS + interferon-γ (IFN-γ)
RAW 264.7 cells (1x106 cells/500 μL/well) were allowed to
adhere to tissue culture wells for 2 h. After 2 h, cells were
treated with medium, resveratrol, pterostilbene, morin hy-
drate, nicotinic acid, or quercetin (16 μM of each com-
pound in 100 μL medium; dissolved in 0.2% DMSO) for 60
min (pretreatment). Cells were then challenged with LPS
(10 ng/well; 400 μL) alone, LPS+ IFN-γ (10 ng+50 U/well)
or medium alone and incubated in an incubator at 37°C in
a humidified, 5% CO2/95% air atmosphere, for 36 h. After
incubation, the supernatants were collected and stored at
−20°C. Levels of NO were determined by measuring the
amount of nitrite, a stable metabolic product of nitric oxide,
as previously reported [17]. The assay mixture contained
medium (100 μL) plus Griess reagent (100μL), and absorp-
tion was measured at 570 nm using a “Microplate Reader”
(MR 5000; Dynatech Laboratories, Inc. Chantilly, VA,
USA). The amount of nitrite was determined by compari-
son of unknowns using a NaNO2 standard curve. The NO
detection limit was 0.20 nM [18].
Effects of resveratrol, pterostilbene, morin hydrate,
nicotinic acid, and quercetin on the secretion of TNF-α by
LPS-stimulated RAW 264.7 cells
RAW 264.7 cells (1x106 cells/500 μL/well) were allowed to
adhere to tissue culture wells for 2 h. After 2 h, cells weretreated with resveratrol, pterostilbene, morin hydrate, nico-
tinic acid, or quercetin (16 μM of each compound in 100
μL medium; dissolved in 0.2% DMSO) for 60 min (pretreat-
ment). Cells were then challenged with LPS (10 ng/well;
400 μL) or medium alone and incubated at 37°C in a hu-
midified, 5% CO2/95% air atmosphere for 4 h. After 4 h in-
cubation, supernatants were collected and stored at -20°C.
The levels of TNF-α in supernatants were measured by
Quantikine M ELISA kit (R&D System, Minneapolis, MN,
USA) according to the manufacturer’s instructions [5-7].
The lower limit of detection for TNF-α by this method is
approximately, 5.0 pg/mL [5].
Effects of resveratrol, pterostilbene, morin hydrate, and
quercetin on NF-κB activation in LPS-stimulated HEK293T
cells (transfectants)
Human embryonic kidney cells (HEK293T) were cultured
in DMEM medium supplemented with 10% fetal bovine
serum. The cells were seeded into 12-well Costar plates
(Corning) at a density of 2x105 cells/well and incubated
overnight (12 h) in an incubator in a humidified, 5% CO2/
95% air atmosphere at 37°C. After 12 h, the cells
(HEK293T) were transfected with Flag-TLR4 wild type
along with pELAM-luciferase (NF-κB reporter; 500 ng/
well) and β-gal reporter plasmids (100 ng/well) plus MD-2
and CD14 constructs (3 ng/well of each) for 20 h as
described previously [19]. After 20 h, the cells were washed
with 1 x PBS, and pretreated with medium only or 40 μM
of resveratrol, pterostilbene, morin hydrate or quercetin for
1 h, and washed again with 1 x PBS. The washed cells were
stimulated with LPS (5 ng/well) for 5 h, then cells were
lysed in 1 x reporter assay lysis buffer (Promega, Madison,
WI, USA), and β-galactosidase and luciferase activities
(Promega, Madison, WI, USA) were measured by Berthold
LB 9507 Luminometer (Berthold Technologies, Oak Ridge,
TN, USA). β-galactosidase was used as a control plasmid
for normalizing transfection efficiencies and luciferase ac-
tivities. The relative luminescence activity was calculated by
normalizing each sample’s luciferase activity for constitutive
β-galactosidase activity measured within the same sample,
and represented as “relative luciferase units” (RLU) as
described earlier [19]. Based on the expression of β-
galactosidase activity in individual cells for each compound,
the transfection efficiency was consistently >90%, as
assessed by in situ β-galactosidase by using staining kit of
Stratagene (Stratagene, La Jolla, CA, USA). Cell viability
was >95% in all the treatments [20].
Effects of resveratrol, pterostilbene, morin hydrate,
nicotinic acid, (niacin), and quercetin on expression of
TNF-α, IL-1β, IL-6, and iNOS genes in LPS-stimulated RAW
264.7 cells
RAW 264.7 cells (1x106 cells/well in 1.0 mL medium)
were allowed to adhere to the bottom of 100 x 20 mm
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removed, and cells were washed extensively with
medium three times. The cells were treated with resvera-
trol, pterostilbene, morin hydrate, nicotinic acid, quer-
cetin, δ-tocotrienol, or riboflavin (16 μM of each
compound, dissolved in 0.2% DMSO) for 2 h. Then all
the wells were challenged with LPS (10 ng/well; 400 μL),
and incubated at 37°C in an incubator in a humidified,
5% CO2/95% air atmosphere for 4 h.
Similarly, thioglycolate-elicited peritoneal macrophages
were prepared from 8-week-old C57BL/6 and BALB/c
female mice as described previously [16,17]. Macro-
phages from both groups (1x107/well) were allowed to
adhere for 2 h to tissue culture wells, cells were treated
with resveratrol, pterostilbene, morin hydrate, nicotinic
acid, quercetin, δ-tocotrienol, or riboflavin (40 μM of
each compound, dissolved in 0.4% DMSO) for 2 h. After
2 h, wells were challenged with LPS (10 ng/well in 400
μL medium), and incubated at 37°C in a humidified, 5%
CO2/95% air atmosphere for 4 h. After LPS stimulation,
assay mixtures of all treatments were centrifuged at
2,000 rpm for 20 min. The cells were then harvested,
and the total cellular RNA was extracted from each pel-
let with RNeasy mini kit (QIAGEN Sciences, German
town, MD, USA) according to the instructions of the
manufacturer, and gene analyses were performed on the
purified RNA after its conversion to DNA as described
earlier [5,21]. The cDNA for each treatment was ampli-
fied and analyzed by real-time polymerase chain reaction
(RT-PCR) to quantify gene expression of TNF-α, IL-1β,
IL-6 and iNOS by using 1-step RT-PCR kit (QIAGEN
Science, Chatsworth, CA, USA) according to the manu-
facturer’s instructions [22]. The viability of LPS-
stimulated thioglycolate-elicited peritoneal macrophages
and RAW 264.7 cells was determined by trypan blue dye
exclusion method or a quantitative colorimetric assayTable 1 Resveratrol, pterostilbene, morin hydrate, and querce
NO Assay mixture Resveratrol Pterostilbene
Average digital values of relati
1 Medium+ cells = A 87458 87458
2 A+DMSO control2 95222± 2014 (100)3 95222± 2014(100)3
3 10 μM 7376± 107 (8) 27543 ± 947 (29)
4 20 μM 6996± 143 (7) 24177± 1775 (25)
5 40 μM 2742± 138 (3) 23574± 1126 (25)
6 80 μM 2261± 124 (2) 21639± 1667 (23)
7 160 μM 1688± 121 (2) 19483± 1207 (20)
8 320 μM 1590 ± 92 (2) 13380± 1341 (14)
1 Chymotrypsin-like activity was quantitated by measuring luminescence after treating RA
resveratrol, pterostilbene, morin hydrate, nicotinic acid, or quercetin as described in Meth
Luminometer.
2Medium+RAW 264.7 whole cells + 0.2% dimethyl sulfioxide (DMSO) was used as c
parenthesis. *Similar results were reported in Lipids in Health and Disease 2011, 10with 3-(4,5)-dimethylthiozol-2,5-tetrazolium bromide
(MTT) as described previously [20].
Statistical analyses
Stat View software (version 4.01, Abacus Concepts,
Berkeley, CA) was used for the analyses of treatment-
mediated effects as compared to control group. Treatment-
mediated differences were detected with a two-way
ANOVA, and when the F test indicated a significant effect,
differences between the means were analyzed by a Fisher’s
protected least significant difference test. Data were
reported as means±SD in text and Tables. The statistical
significance level was set at 5% (P< 0.05).
Results
The results are presented in the same Figure in two dif-
ferent formats: ‘A’ shows the actual measured or calcu-
lated values for each treatment and controls, and ‘B’
shows the percent change based on actual calculated
values for each treatment compared to control values.
Inhibitory effects of resveratrol, pterostilbene, morin
hydrate, nicotinic acid, (niacin), and quercetin on
chymotrypsin-like, trypsin-like, and post-glutamase
proteasomal activities in RAW 264.7 whole cells
Twenty S (20 S) proteasomes contain three distinct subu-
nits (X, Y, and Z), with well characterized protease sites;
subunits X (β5), Y (β1), and Z (β2) display chymotrypsin-
like, trypsin-like, and post-glutamase activities, respectively
[22,23]. This series of experiments was designed to deter-
mine whether resveratrol, pterostilbene, morin hydrate, and
nicotinic acid (niacin) act as proteasome inhibitors, by
measuring their effects on chymotrypsin-like, trypsin-like
and post-glutamase proteasomal activities. Quercetin,
which was previously shown to inhibit proteasomal enzym-
atic activity, was used as a positive control [5].tin inhibit chymotrypsin-like proteasomal activity1
Morin Hydrate Nicotinic acid Quercetin*
ve luminescence units (RLU)
87458 87458 87458
95750 ± 2014 (100)3 95750 ± 2014 (100)3 95750± 2014 (100)3
89557 ± 1958 (94) 95240± 2020 (99) 61823± 2206 (65)
67338 ± 1626 (71) 95342± 1896 (100) 36772± 1201 (39)
55078 ± 1444 (58) 94232± 1962 (98) 19805 ± 732 (21)
41178 ± 1099 (43) 94155± 1926 (98) 17478 ± 783 (18)
33814 ± 134 (36) 95165± 1966 (99) 13827 ± 621 (15)
27448± 88 (29) 94124± 2038 (98) 5896 ± 321 (6)
W 264.7 whole cells (1x104) with various concentrations (10 μM - 320 μM) of
ods. The relative luminescence units (RLU) of assays were read in a Promega Plate
ontrol. 3Percentages based on digital values of RLU compared to control are in
:177.
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inhibited by resveratrol, pterostilbene, morin hydrate, and
quercetin (positive control), but not by nicotinic acid
(Table 1). Inhibition by morin hydrate and quercetin was
highly dose-dependent, whereas inhibition by resveratrol
and pterostilbene was mildly dose-dependent for the con-
centrations tested (10 μM to 320 μM; Table 1).
Chymotrypsin-like activity was inhibited by >90% and
>70% (P< 0.02) by resveratrol and pterostilbene, respect-
ively, at the lowest concentrations tested (10 μM; Table 1).
Quercetin and morin hydrate were somewhat less potent,
inhibiting chymotrypsin-like activity by 61% and 29%, re-
spectively, (P< 0.05) at 20 μM concentration (Table 1).
Thus, of the compounds tested, resveratrol appears to be
the most potent inhibitor of chymotrypsin-like activity. ForFigure 2 Resveratrol, pterostilbene, morin hydrate, and quercetin inh
like activity was quantitated by measuring luminescence after treatment of
pterostilbene, morin hydrate, nicotinic acid, or quercetin. Cell viability excee
treatment, and triplicate analyses of each sample were performed. Values in
P< 0.05. CTL = Control (Medium + RAW 264.7 whole cells + 0.2 % DMSO); R
Nico =Nicotinic acid; Quer =Quercetin-HCL. Figure A= Actual Relative Lum
values compared to control.subsequent experiments, we selected a single concentration
(20 μM) for testing each of these compounds. The inhibi-
tory effect of these compounds on chymotrypsin-like activ-
ity at a concentration of 20 μM is presented in Figure 2.
Proteasomal trypsin-like activity was inhibited by 86%,
66% (P< 0.02), 26%, and 59% (P< 0.05) with 20 μM
resveratrol, pterostilbene, morin hydrate, and quercetin,
respectively (Figure 3). Similarly, post-glutamase activity
was inhibited by 78%, 73% (P< 0.02), 14% and 25%
(P< 0.05) with 20 μM resveratrol, pterostilbene, morin
hydrate, and quercetin, respectively (Figure 4). Nicotinic
acid failed to inhibit both trypsin-like and post-glutamase
activities of the proteasome (Figures 3 and 4). The data
presented in Figures 2, 3 and 4 demonstrate that, of the
compounds tested, resveratrol and pterostilbene are theibit chymotrypsin-like proteasomal activity. Relative chymotrypsin-
RAW 264.7 whole cells (1x104 cells/well) with 20 μM of resveratrol,
ded 95% in all the treatments. Data are means ± SD, n= 3 per
a column not sharing a common symbol are significantly different at
esv = Resveratrol; Pter = Pterostilbene; Mori =Morin hydrate;
inescence Unit (RLU) values. Figure B = Percentages of actual RLU
Figure 3 Resveratrol, pterostilbene, morin hydrate, and quercetin inhibit trypsin-like proteasomal activity. Relative trypsin-like activity
was quantitated by measuring luminescence after treatment of RAW 264.7 whole cells (1x104 cells/well) with 20 μM of resveratrol, pterostilbene,
morin hydrate, nicotinic acid, or quercetin. Cell viability exceeded 95% in all the treatments. Data are means ± SD, n= 3 per treatment, and
triplicate analyses of each sample were performed. Values in a column not sharing a common symbol are significantly different at P< 0.05.
CTL=Control (Medium+RAW 264.7 whole cells + 0.2 % DMSO); Resv=Resveratrol; Pter = Pterostilbene; Mori =Morin hydrate; Nico=Nicotinic acid;
Quer =Quercetin-HCL. Figure A= Actual Relative Luminescence Unit (RLU) values. Figure B = Percentages of actual RLU values compared to control.
Qureshi et al. Lipids in Health and Disease 2012, 11:76 Page 7 of 17
http://www.lipidworld.com/content/11/1/76most potent inhibitors of all three proteasomal enzymatic
activities.
Resveratrol, pterostilbene, morin hydrate, nicotinic acid,
and quercetin inhibit production of NO by RAW 264.7
cells stimulated with LPS alone or LPS plus interferon-γ
(IFN-γ)
We recently reported that δ-tocotrienol, quercetin, ribofla-
vin, and dexamethasone inhibited NO production by LPS-
stimulated RAW 264.7 cells and thioglycolate-elicited peri-
toneal macrophages derived from C57BL/6 and BALB/c
mice [5]. Consequently, we were interested in determining
whether resveratrol, pterostilbene, morin hydrate, and nico-
tinic acid would have similarly suppressive effects on NO
responses to LPS-stimulation. RAW 264.7 cells were pre-
treated with resveratrol, pterostilbene, morin hydrate,niacin, or quercetin (positive control; 16 μM of each com-
pound) for 60 min, followed by stimulation with LPS alone
(10 ng/well) or LPS plus IFN-γ (10 ng+50 U/well) at room
temperature for 36 h; NO was measured in cell culture
supernatants. IFN-γ was used because it augments the NO
response of LPS-stimulated macrophages [21]. Significant
(P<0.05) inhibition of NO production by RAW 264.7 cells
stimulated with LPS alone or LPS plus IFN-γ was attained
with resveratrol (45%), pterostilbene (41%), morin hydrate
(42%), and quercetin (33%), but not with nicotinic acid
(Figure 5A,B). The extent of NO suppression did not differ
markedly for the four compounds, but inhibition of NO
production was more pronounced in RAW 264.7 cells sti-
mulated with LPS plus IFN-γ (66%, 54%, 60%, 52% respect-
ively; P<0.02) compared to those stimulated with LPS
alone (Figure 5A,B).
Figure 4 Resveratrol, pterostilbene, morin hydrate, and quercetin inhibit post-glutamase proteasomal activity. Relative post-glutamase
activity was quantitated by measuring luminescence after treatment of RAW 264.7 whole cells (1x104 cells/well) with 20 μM of resveratrol,
pterostilbene, morin hydrate, nicotinic acid, quercetin or medium alone (control). Cell viability exceeded 95% in all the treatments. Data are
means ± SD, n = 3 per-treatment, and triplicate analyses of each sample were performed. Values in a column not sharing a common symbol are
significantly different at P <0.05. CTL = Control (Medium+RAW 264.7 whole cells + 0.2% DMSO); Resv = resveratrol; Pter = pterostilbene;
Mori =morin hydrate; Nico = nicotinic acid; Quer = quercetin-HCL. Figure A= actual relative luminescence unit (RLU) values. Figure B= Percentages
of actual RLU values compared to control.
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and quercetin inhibit secretion of TNF-α by LPS-
stimulated RAW 264.7 cells
It is well established that TNF-α is among the earliest and
most important pro-inflammatory cytokines produced in
response to a variety of inflammatory stimuli, and we have
previously demonstrated that a number of naturally-
occurring proteasome inhibitors suppress secretion of
TNF-α by LPS-stimulated macrophages in vitro and in vivo
[5,22,23]. Consequently, this series of experiments was con-
ducted to determine whether resveratrol, pterostilbene,
morin hydrate, nicotinic acid and quercetin had similarly
suppressive effects on TNF-α secretion by LPS-stimulated
RAW 264.7 cells.RAW 264.7 macrophage-like cells were pretreated for
1 h with resveratrol, pterostilbene, morin hydrate, nicoti-
nic acid, or quercetin (16 μM of each), followed by
stimulation with LPS (10 ng/well) and measurement of
TNF-α in supernatants 4 h after LPS stimulation.
Resveratrol (59%), pterostilbene (55%), morin hydrate
(44%), and quercetin, (48%) significantly (P< 0.02)
inhibited LPS-induced secretion of TNF-α, whereas,
nicotinic acid (22%) produced only (P< 0.05) moderate
inhibition (Figure 6). We previously demonstrated that
both chymotrypsin-like and trypsin-like enzymatic pro-
teasomal activity of the proteasome had to be inhibited
in order to suppress TNF-α secretion by LPS stimulated
macrophages [22,23]. Thus, our findings that these
Figure 5 Resveratrol, pterostilbene, morin hydrate, and quercetin inhibit production of NO by RAW 264.7 cells treated with LPS alone,
or LPS plus interferon-γ (IFN-γ). NO levels were measured in supernatants of RAW 264.7 treated with resveratrol, pterostilbene, morin hydrate,
nicotinic acid, quercetin (16 μM) or medium alone (control) for 1 h, then challenged with LPS (10 ng/well) alone, LPS + IFN-γ (10 ng+ 50 U/well)
or medium alone (negative control) for 36 h. Cell viability exceeded 95% for all treatments. Data are means ± SD, n= 3 per treatment, and
triplicate analyses of each sample were performed. Values in a column not sharing a common symbol are significantly different at P< 0.05. CTL=
Control (Medium+RAW 264.7 cells + 0.2% DMSO); Resv = Resveratrol; Pter = Pterostilbene; Mori =Morin hydrate; Nico=Nicotinic acid;
Quer=Quercetin-HCL. Figure A= Actual Relative Luminescence Unit (RLU) values. Figure B = Percentages of actual RLU values compared to control.
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http://www.lipidworld.com/content/11/1/76compounds inhibited both chymotrypsin-like and
trypsin-like activities of the proteasome (Figures 2 and
3) are consistent with their ability to inhibit TNF-α se-
cretion by LPS-stimulated RAW 264.7 cells (Figure 6).
Inhibition of NF-κB activation in LPS-stimulated HEK293T
cells by resveratrol, pterostilbene, morin hydrate, and
quercetin
We recently hypothesized that increased NO levels, asso-
ciated with ageing, may be attributable to increased deg-
radation of phosphorylated IκB by ageing proteasomes,resulting in enhanced NF-κB activation. In studying the
potential mechanisms by which a variety of proteasome
inhibitors suppress overproduction of inflammatory cyto-
kines associated with ageing, we determined that they
inhibited NF-κB activation [5]. NF-κB is normally com-
plexed with IκB in the cytoplasm and becomes activated
when IκB is phosphorylated, ubiquitinated, and subse-
quently degraded by the proteasome [24]. Once it dissoci-
ates from IκB, NF-κB translocates to the nucleus where it
binds to promoter sites of pro-inflammatory genes such as
TNF-α and iNOS [24].
Figure 6 Resveratrol, pterostilbene, morin hydrate, nicotinic acid and quercetin inhibit TNF-α secretion by LPS treated RAW 264.7 cells.
TNF-α levels were measured in supernatants of RAW 264.7 treated with resveratrol, pterostilbene, morin hydrate, nicotinic acid, quercetin (16 μM)
or medium alone (control) for 1 h, then challenged with LPS (10 ng/well; 400 μL) or medium alone for 4 h. Cell viability exceeded 95% for all
treatments. Data are means ± SD, n= 3 per treatment, and triplicate analyses of each sample were performed. Values in a column not sharing a
common symbol are significantly different at P< 0.05. CTL = Control (Medium+RAW 264.7 cells + 0.2% DMSO); Resv = Resveratrol;
Pter = Pterostilbene; Mori =Morin hydrate; Nico =Nicotinic acid; Quer = Quercetin-HCL. Figure A =Actual Relative Luminescence Unit (RLU) values.
Figure B = Percentages of actual RLU values compared to control.
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date acted by blocking the degradation of phosphory-
lated and ubiqutinated IκB by the proteasome, thereby
preventing NF-κB activation [5-7,25]. For this series of
experiments we wanted to determine if resveratrol, pter-
ostilbene, and morin hydrate, behave similarly to previ-
ously tested proteasome inhibitors, by inhibiting NF-κB
activation in LPS-stimulated HEK293T cells; quercetin,
was used as a positive control. Significant inhibition
(P< 0.02) of LPS-induced NF-κB activation, compared
to medium controls, was achieved with resveratrol
(33%), pterostilbene (45%), morin hydrate (30%), and
quercetin (22%) compared to controls (Figure 7). Thus,
the capacity of each of these compounds to inhibit pro-
duction of NO, and secretion of TNF-α in response toLPS-stimulation, appears to be dependent upon their
ability to suppress LPS-induced NF-κB activation.
Inhibitory effects of resveratrol, pterostilbene, morin
hydrate, nicotinic acid, and quercetin on expression of
TNF-α, IL-1β, IL-6, and iNOS genes in LPS-stimulated RAW
264.7 cells
In an earlier study, we demonstrated that several
naturally-occurring proteasome inhibitors (quercetin,
riboflavin, and δ-tocotrienol) suppress expression of
TNF-α and iNOS genes in LPS-stimulated thioglycolate-
elicited peritoneal macrophages derived from several
strains of mice [5]. Other inflammatory cytokines (e.g.
IL-1β. IL-6), have also been implicated in age-related
diseases, so the following experiment was conducted to
Figure 7 Resveratrol, pterostilbene, morin hydrate, and quercetin inhibit NF-κB activation in LPS-stimulated HEK293T cells. Relative
luminescence of an NF-κB reporter compared to a β-galactosidase reporter (control) was measured to determine the extent of NF-κB activation in
HEK293T cells treated with resveratrol, pterostilbene, morin hydrate, quercetin (40 μM) or medium alone for 1 h, then challenged with LPS (5 ng/
well) for 5 h. Cell viability was >95% in all the treatments. Data are means ± SD, n = 2 per treatment, and duplicate analyses of each sample
were performed. Values in a column not sharing a common symbol are significantly different at P< 0.05. CTL = Control (Medium+HEK293T cells
+ 0.4% DMSO); Resv = Resveratrol; Pter = Pterostilbene; Mori =Morin hydrate; Quer =Quercetin-HCL. Data presented represent the percent
inhibition of NF-κB activation compared to control.
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http://www.lipidworld.com/content/11/1/76determine whether resveratrol, pterostilbene, morin hy-
drate, and nicotinic acid have the capacity to suppress
expression of IL-6, in addition to TNF-α and iNOS
genes, in LPS-stimulated RAW 264.7 cells.Table 2 Resveratrol, pterostilbene, morin hydrate, nicotinic a
and iNOS genes in LPS-stimulated RAW 264.7 cells1
NO Treatments RT-PCR data (*Ratios of optic
TNF-α
1 Media + Cells = A 0.05
2 A+ LPS (10 ng/well) = B 0.83
3 B+ 0.2% DMSO=C 0.80 ± 0.03a (100)2 1.
4 C + Resveratrol (16.0 μM) 0.18 ± 0.02e (23) 0
5 C+ Pterostilbene (16.0 μM) 0.38 ± 0.03d (48) 0
6 C+Morin hydrate (16.0 μM) 0.55 ± 0.03b (69) 0
7 C+Nicotinic acid (16.0 μM) 0.76 ± 0.05a (95) 1
8 C+Quercetin (16.0 μM) 0.45 ± 0.02c (56) 0
1RAW 264.7 cells were treated with resveratrol, pterostilbene, morin hydrate, nicotin
well) for 4 h. Total RNA was extracted, reverse transcribed, and the resulting DNA w
IL-1β, IL-6, and iNOS genes [5,21].
Cell viability was >95% in all treatments. Data are means ± SD, n= 3 (triplicate anal
2Percentages of *digital values of relative optical density of each cytokine/β-actin o
common superscript letter are significantly different at P< 0.05.RAW 264.7 cells (1x107 cells/well) were allowed to ad-
here for 4 h in the wells, and after 4 h, cells were treated
with resveratrol, pterostilbene, morin hydrate, or nicoti-
nic acid (16 μM of each compound in 0.2% DMSO) forcid, and quercetin inhibit expression of TNF-α, IL-1β, IL-6,




32 ± 0.03a (100)2 0.96 ± 0.03a (100)2 1.04 ± 0.02a (100)2
.51 ± 0.03e (39) 0.21 ± 0.0e (22) 0.65 ± 0.02c (63)
.75 ± 0.03d (57) 0.62 ± 0.03c (65) 0.92 ± 0.03b (88)
.92 ± 0.04c (70) 0.63 ± 0.02c (66) 0.53 ± 0.03d (51)
.12 ± 0.02b (85) 0.75 ± 0.03b (78) 0.66 ± 0.05c (64)
.22 ± 0.02f (17) 0.25 ± 0.0d (26) 0.37 ± 0.03e (36)
ic acid, or quercetin (16 μM) for 1 h, followed by treatment with LPS (10 ng/
as amplified and analyzed by real time PCR to quantitate expression of TNF-α,
ysis of each sample).
f each treatment are in parenthesis. a-fValues in a column not sharing a
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http://www.lipidworld.com/content/11/1/761 h; quercetin (16 μM) was used as a positive control.
All wells were subsequently challenged with LPS (10 ng/
well), and incubated at 37°C in an incubator for 4 h.
Total RNA was extracted using the RNeasy mini kit, and
analyzed by RT-PCR to quantify gene expression of vari-
ous cytokines. TNF-α, IL-1β, IL-6, and iNOS gene ex-
pression in LPS-stimulated RAW 264.7 cells was
significantly (P<0.05) inhibited by all compounds tested,
with one exception; nicotinic acid failed to inhibit ex-
pression of the TNF-α gene (Table 2).
Quercetin (positive control) inhibited expression of
TNF-α, IL-1β, and IL-6 genes by 44%, 83%, and 74%, re-
spectively, compared to controls (Table 2). Of the ex-
perimental compounds tested, the most pronounced
inhibition of TNF-α, IL-1β, and IL-6 gene expression
(77%, 61%, and 78% suppression, respectively; P<0.02)
compared to respective controls, was obtained with
resveratrol. Inhibition of TNF-α, IL-1β, and IL-6 gene
expression was somewhat less pronounced with pteros-
tilbene (52%, 43%, and 35%, respectively; P< 0.05), and
morin hydrate (31%, 30%, and 34% inhibition, respect-
ively) compared to respective controls. In contrast,
morin hydrate was the most potent inhibitor of iNOS
gene expression (49%; P<0.05; Table 2). The results of
gene expression inhibition studies for TNF-α and iNOS
genes were generally consistent with those of secretion
of TNF-α and NO production. Thus, these experiments
support the conclusion that resveratrol, pterostilbene,
and morin hydrate exert anti-inflammatory effects, at
least in part, due to their ability to suppress gene expres-
sion of TNF-α, iNOS, IL-1β, and IL-6 in LPS-stimulated
RAW 264.7 cells. Nicotinic acid, in contrast, did not
suppress expression of the TNF-α gene, and its capacity
to suppress expression of the IL-1β and IL-6 genes was
also relatively modest; it did, however, demonstrateTable 3 Resveratrol, pterostilbene, morin hydrate, nicotinic a
and iNOS genes in peritoneal macrophages from C57BL/6 mi
NO Treatments RT-PCR data (Ratios of digital va
TNF-α I
1 Media + Cells = A 0.05
2 A+ LPS (10 ng/well) = B 0.45
3 B+ 0.4% DMSO=C 0.36 ± 0.02a (100)2 6.89 ± 2
4 C+ Resveratrol (40.0 μM) 0.10 ± 0.01c (28) 1.39 ±
5 C+ Pterostilbene (40.0 μM) 0.11 ± 0.01c (31) 1.74 ±
6 C+Morin hydrate (40.0 μM) 0.14 ± 0.05b (39) 1.87 ±
7 C+Nicotinic acid (40.0 μM) 0.33 ± 0.03a (92) 6.27 ±
8 C+Quercetin (40.0 μM) 0.11 ± 0.04c (31) 2.14 ±
1Thioglycolate-elicited peritoneal macrophages from 8-week-old C57BL/6 mice were
in all the treatments. Data are means ± SD, n= 3 (triplicate analysis of each sample).
Cell viability was >95% in all the treatments. Data are means ± SD, n = 3 (triplicate a
2Percentages of digital values of relative optical density of each cytokine/β-actin of
a-cValues in a column not sharing a common superscript letter are significantly differelatively potent inhibition of iNOS gene expression
(36%) compared to controls (Table 2).
Inhibitory effects of resveratrol, pterostilbene, morin
hydrate, nicotinic acid, and quercetin on expression of
TNF-α, IL-1β, IL-6, and iNOS genes in LPS-stimulated,
peritoneal macrophages from 8-week-old C57BL/6 and
BALB/c mice
In order to confirm the results obtained with cultured
RAW 264.7 cells (Table 2), we decided to determine the
effects of resveratrol, pterostilbene, morin hydrate, and
nicotinic acid on TNF-α, IL-1β, IL-6 and iNOS gene ex-
pression in LPS-stimulated, thioglycolate-elicited peri-
toneal macrophages from C57BL/6 and BALB/c mice;
quercetin was used as a positive control. Cells (1x106/
well) were adhered to tissue culture plate for 4 h, after
which cells were treated with resveratrol, pterostilbene,
morin hydrate, nicotinic acid, or quercetin (40 μM/well
in 0.2% DMSO) for 1 h. LPS (10 ng/well) was then
added to each well and incubated for 4 h. After 4 h total
cellular RNA was extracted and reverse-transcribed, and
gene expression was quantified by RT-PCR [5,21].
Expression of TNF-α, IL-1β, IL-6, and iNOS genes in
LPS-stimulated, thioglycolate-elicited peritoneal macro-
phages from C57BL/6 mice was significantly (P< 0.02)
inhibited by resveratrol, pterostilbene, morin hydrate, and
quercetin (positive control); nicotinic acid did not signifi-
cantly suppress expression of any of these genes (Table 3).
The most pronounced inhibition of TNF-α, IL-1β, and
IL-6 gene expression was attained with resveratrol (72%,
80%, and 82%, respectively) and pterostilbene (69%, 75%,
and 81% respectively). Resveratrol (31%), pterostilbene
(34 %), morin hydrate (39%), and quercetin (36%) were also
potent inhibitors of iNOS gene expression (Table 3) com-
pared to respective controls. Nicotinic acid (15%) was onlycid, and quercetin inhibit expression of TNF-α, IL-1β, IL-6,
ce1




.01a (100)2 12.34 ± 1.96a (100)2 5.67 ± 1.90a (100)2
0.04c (20) 2.16 ± 0.60c (18) 3.93 ± 1.50b (69)
0.48b (25) 2.33 ± 0.82c (19) 3.76 ± 1.40b,c (66)
0.49b (27) 3.03 ± 1.03b (25) 3.47 ± 0.03b,c (61)
0.42a (91) 10.86 ± 0.91a (88) 4.81 ± 0.66a (85)
0.46b (31) 3.24 ± 0.93b (26) 3.65 ± 1.18b,c (64)
treated with resveratrol, pterostilbene, morin hydrate, Cell viability was >95%
nalysis of each sample).
each treatment are in parenthesis.
rent at P< 0.05.
Table 4 Resveratrol, pterostilbene, morin hydrate, nicotinic acid, and quercetin inhibit expression of TNF-α, IL-1β, IL-6,
and iNOS genes in peritoneal macrophages from BALB/c mice1
NO Treatments RT-PCR data (Ratios of digital values of optical density of gene expression of cytokines/β-actin).
TNF-α IL-1β IL-6 iNOS
1 Media + Cells = A 0.05 0.05 0.1 0.2
2 A+ LPS (10 ng/well) = B 0.62 8.27 14.45 7.76
3 B+ 0.4% DMSO=C 0.74 ± 0.11a (100)2 10.68 ± 1.18a (100)2 15.68 ± 1.13a (100)2 9.85 ± 1.04a (100)2
4 C+ Resveratrol (40.0 μM) 0.28 ± 0.06c (38) 3.25 ± 0.97b (30) 4.43 ± 1.23b,c (28) 7.18 ± 0.88b (73)
5 C+ Pterostilbene (40.0 μM) 0.35 ± 0.08b (47) 3.55 ± 1.00b (33) 5.08 ± 0.76b,c (32) 6.68 ± 1.10b (68)
6 C+Morin hydrate (40.0 μM) 0.32 ± 0.09c (43) 3.75 ± 1.04b (35) 5.68 ± 1.09b (36) 7.28 ± 0.97b (74)
7 C+Nicotinic acid (40.0 μM) 0.65 ± 0.11a (88) 9.74 ± 1.33a (91) 12.76 ± 0.91a (81) 8.17 ± 1.05a (83)
8 C+Quercetin (40.0 μM) 0.30 ± 0.12c (41) 3.63 ± 1.40b (34) 6.10 ± 0.77b (39) 7.12 ± 1.07b (72)
1Thioglycolate-elicited peritoneal macrophages from 8-week-old BALB/c mice were treated with resveratrol, pterostilbene, morin hydrate, nicotinic acid, or
quercetin (40 μM) for 1 h, followed by treatment with LPS (10 ng/well) for 4 h. Total RNA was extracted, reverse transcribed, and the resulting DNA was amplified
and analyzed by real time PCR to quantitate expression of TNF-α, IL-1β, IL-6, and iNOS genes [5,21]. Cell viability was >95% in all the treatments. Data are
means ± SD, n = 3 (triplicate analysis of each sample).
2Percentages of digital values of relative optical density of each cytokine/β-actin of each treatment are in parenthesis.
a-cValues in a column not sharing a common superscript letter are significantly different at P< 0.05.
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Results with peritoneal macrophages from BALB/c mice
(Table 4) were almost identical to those attained with
C57BL/6 mice (Table 3).
In summary, resveratrol, pterostilbene, and morin hy-
drate significantly (P <0.02) reduced TNF-α, IL-1β, IL-6
and iNOS mRNA expression in LPS-stimulated RAW
264.7 cells and thioglycolate-elicited peritoneal macro-
phages derived from C57BL/6 or BALB/c mice. Of the
compounds tested, resveratrol and pterostilbene appear
to produce slightly more potent inhibition of TNF-α, IL-
1β, and IL-6 gene expression than morin hydrate. iNOS
gene expression, in contrast, is at least as susceptible to
inhibition by morin hydrate, as it is to inhibition by
resveratrol and pterostilbene. Nicotinic acid failed to in-
hibit TNF-α, IL-1β, IL-6 and iNOS gene expression in
LPS-stimulated peritoneal macrophages from either
C57BL/6 or BALB/c mice, and produced only mild in-
hibitory effects in LPS-stimulated RAW 264.7 cells.
Inhibitory effects of δ-tocotrienol and riboflavin on
expression of TNF-α, IL-1β, IL-6, and iNOS genes in RAW
264.7 cells and peritoneal macrophages from 8-week-old
C57BL/6 and BALB/c mice stimulated with LPS
We have now demonstrated that resveratrol, pterostilbene,
morin hydrate, and quercetin have the capacity to suppress
gene expression of IL-1β and IL-6, in addition to TNF-α
and iNOS genes, in LPS-stimulated RAW 264.7 cells and
peritoneal thioglycolate-elicited macrophages derived from
C57BL/6 and BALB/c mice (Tables 2, 3, 4). We had previ-
ously studied the ability of other proteasome inhibitors (e.g.
δ-tocotrienol and riboflavin) to inhibit expression of TNF-α
and iNOS genes under a variety of conditions [5], but had
not tested their ability to inhibit IL-1β, and IL-6 gene ex-
pression. Consequently, this series of experiments wasdesigned to determine whether δ-tocotrienol and riboflavin
would produce results comparable to resveratrol, pterostil-
bene, morin hydrate, and inhibit IL-1β, and IL-6 gene ex-
pression in LPS-stimulated macrophages using identical
conditions to those described above for Tables 2, 3 and 4.
Expression of TNF-α, IL-1β, IL-6, and iNOS genes in
LPS-stimulated RAW 264.7 cells and peritoneal macro-
phages from both C57BL/6 and BALB/c mice was sig-
nificantly (P<0.05) inhibited by both δ-tocotrienol and
riboflavin (Table 5). For virtually all genes and all cells
tested, the extent of inhibition attained with δ-
tocotrienol was generally greater than that attained with
riboflavin. Inhibition of iNOS in BALB/c mice was the
only exception; the degree of inhibition by δ-tocotrienol
and riboflavin was comparable. Similarly, the extent to
which δ-tocotrienol and riboflavin inhibited IL-1β and
IL-6 gene expression was comparable, or slightly greater
than that observed for TNF-α gene expression in all cell
systems tested. Thus, the anti-inflammatory properties
of δ-tocotrienol and riboflavin are not limited to their
ability to suppress TNF-α and iNOS gene expression;
they also suppress expression of IL-1β, and IL-6 genes in
LPS-stimulated RAW 264.7 cells and macrophages
derived from C57BL/6 and BALB/c mice.
Inhibitory effects of δ-tocotrienol combined with
resveratrol, pterostilbene, morin hydrate, nicotinic acid,
or quercetin on TNF-α secretion and nitric oxide (NO)
production by LPS-stimulated peritoneal macrophages
from C57BL/6 mice
The capacity of δ-tocotrienol, quercetin, riboflavin,
resveratrol, pterostilbene, morin hydrate and nicotinic
acid to inhibit TNF-α secretion and NO production by
LPS-stimulated RAW 264.7 cells and macrophages
derived from C57BL/6 and BALB/c has been established.
Table 5 δ-Tocotrienol and riboflavin inhibit expression of TNF-α, IL-1β, IL-6, and iNOS genes in LPS-stimulate RAW
264.7 cells, and peritoneal macrophages derived from C57BL/6 or BALB/c mice1
NO Treatments RT-PCR data (Ratios of digital values of optical density of gene expression of cytokines/β-actin).
TNF-α IL-1β IL-6 iNOS
RAW 264.7 cells.
1 Media + Cells = A 0.05 0.05 0.1 0.2
2 A+ LPS (10 ng/well) = B 0.83 1.35 0.98 1.12
3 B+ 0.2% DMSO=C 0.80 ± 0.03a (100)2 1.32 ± 0.03a (100)2 0.96 ± 0.03a (100)2 1.04 ± 0.02a (100)2
4 C+ δ-Tocotrienol (16.0 μM) 0.32 ± 0.03c (40) 0.33 ± 0.03c (25) 0.41 ± 0.04c (43) 0.42 ± 0.04c (40)
5 C+ Riboflavin (16.0 μM) 0.64 ± 0.04b (80) 0.95 ± 0.03b (72) 0.82 ± 0.04b (85) 0.76 ± 0.03b (73)
8-week-old C57BL/6
1 Media + Cells (macrophages) = A 0 0 0 0
2 A+ LPS (10 ng/well) = B 0.35 5.32 11.67 4.97
3 B+ 0.4% DMSO=C 0.36 ± 0.02a (100)2 6.89 ± 0.86a (100)2 12.34 ± 1.1a (100)2 5.67 ± 0.67a (100)2
4 C+ δ-Tocotrienol (40.0 μM) 0.16 ± 0.08c (45) 2.34 ± 0.42c (34) 1.98 ± 0.24c (16) 2.12 ± 0.56c (56)
5 C+ Riboflavin (40.0 μM) 0.22 ± 0.02b (61) 4.15 ± 0.68b (60) 7.23 ± 0.98b (59) 4.16 ± 0.53b (73)
8-week-old BALB/c
1 Media + Cells (macrophages) = A 0 0 0 0
2 A+ LPS (10 ng/well) = B 0.62 8.27 14.45 7.76
3 B+ 0.4% DMSO=C 0.74 ± 0.05a (100)2 10.67 ± 1.24a (100)2 15.67 ± 1.45a (100)2 9.85 ± 0.88a (100)2
4 C+ δ-Tocotrienol (40.0 μM) 0.39 ± 0.01c (53) 4.16 ± 0.36c (39) 3.45 ± 0.28c (22) 6.64 ± 0.86b (67)
5 C+ Riboflavin (40.0 μM) 0.54 ± 0.03b (73) 6.45 ± 0.91b (60) 4.73 ± 0.22b (30) 7.64 ± 0.67b (78)
1RAW 264.7 cells or thioglycolate-elicited peritoneal macrophages from 8-week-old C57BL/6 or BALB/c mice were treated with δ-tocotrienol or riboflavin (16 μM or
40 μM) for 1 h, followed by treatment with LPS (10 ng/well) for 4 h. Total RNA was extracted, reverse transcribed, and the resulting DNA was amplified and
analyzed by real time PCR to quantitate expression of TNF-α, IL-1β, IL-6, and iNOS genes [5,21].
Cell viability was >95% in all the treatments. Data are means ± SD, n = 3 (triplicate analysis of each sample).
2Percentages of digital values of relative optical density of each cytokine/β-actin of each treatment are in parenthesis. a-cValues in a column not sharing a
common superscript letter are significantly different at P< 0.05.
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supplementation with a combination of δ-tocotrienol
plus either quercetin or riboflavin produced further
decreases in inflammation compared to treatment with
any of these agents alone in chickens [6]. Thus, we
wanted to determine whether combined treatment of
LPS-stimulated peritoneal macrophages with δ-
tocotrienol plus resveratrol, pterostilbene, morin hy-
drate, quercetin, riboflavin or nicotinic acid would pro-
duce further reductions in TNF-α secretion and NO
production compared to treatment with each of these
agents alone. The assay conditions were identical to
those described earlier [5]. As shown in Table 6, when
each of the compounds was tested individually, there
was significant inhibition of TNF-α secretion and NO
production by LPS stimulated macrophages compared to
controls (rows 4–10 vs. row 3), as anticipated. Import-
antly, however, the extent to which TNF-α secretion and
NO production were inhibited by resveratrol, pterostil-
bene, morin hydrate, quercetin, riboflavin and nicotinic
acid was increased when they were combined with δ-
tocotrienol (Table 6; compare row 12 vs. 5; 13 vs. 6; 14vs. 7, etc). These findings suggest additive or synergistic
effects between these compounds, and confirm our earl-
ier findings that combining δ-tocotrienol with either
quercetin or riboflavin reduced markers of inflammation
in chickens [6].
In summary, the collective results presented in this
manuscript strongly support the concept that the in-
flammatory response of macrophages to LPS, one of the
most potent inflammatory stimuli identified to date, can
be markedly suppressed by a variety of proteasome inhi-
bitors that have been FDA approved for human
consumption.
Discussion
The key findings of the current study are that resvera-
trol, pterostilbene and morin hydrate inhibit proteaso-
mal enzymatic activity, as well as the capacity of
macrophages to produce inflammatory cytokines and
NO in response to LPS stimulation. First, we demon-
strated that all three of these compounds inhibited
chymotrypsin-like, trypsin-like, and post-glutamase pro-
teasome enzymatic activity of cultured RAW 264.7
Table 6 Inhibitory effects of quercetin, riboflavin, resveratrol, pterostilbene, morin hydrate and nicotinic acid with or
without δ-tocotrienol on the secretion of TNF-α and production of nitric oxide by LPS-induced peritoneal macrophages
from C57BL/6 mice1
NO Assay mixture Concentration Serum concentration Serum concentration
in μM of TNF-α (pg/mL) of nitric oxide (μM)
1 Medium+Cells = A 0 0
2 A+ LPS (10 ng/well) = B 1098.87 28.89
3 B + 0.2% DMSO2 =C 1056.23 (100)3 28.54 (100)3
4 C+ δ-Tocotrienol =D 5.0 674.56 (64) 18.98 (67)
5 C+Quercetin 40.0 589.98 (56) 20.43 (72)
6 C+ Riboflavin 40.0 502.87 (58) 22.54 (79)
7 C+ Resveratrol 40.0 542.76 (51) 17.56 (61)
8 C+ Pterostilbene 40.0 567.34 (54) 16.87 (59)
9 C+Morin hydrate 40.0 597.42 (57) 19.65 (69)
10 C+Nicotinic acid 40.0 727.71 (69) 23.89 (84)
11 B + 0.2% DMSO=C 1062.45 (100) 27.98 (100)
12 D+Quercetin 40.0 432.87 (41) 14.76 (53)
13 D+ Riboflavin 40.0 465.21 (44) 17.43 (62)
14 D+ Resveratrol 40.0 346.76 (33) 12.67 (45)
15 D+ Pterostilbene 40.0 412.45 (39) 13.25 (47)
16 D+Morin hydrate 40.0 432.67 (41) 15.32 (55)
17 D+Nicotinic acid 40.0 588.56 (55) 18.96 (68)
1Thioglycolate-elicited peritoneal macrophages from 8-week-old C57BL/6 mice were pre treated with quercetin, riboflavin, resveratrol, pterostilbene, morin
hydrate, or nicotinic acid (40 μM) with or without δ-tocotrienol (5 μM) for 1 h, followed by treatment with LPS (10 ng/well). After 4 h (TNF-α) or 36 h (NO) of LPS
challenge, supernatants were collected and assayed for TNF-α and NO, respectively. Cell viability was >95% in all the treatments.
2DMSO=dimethyl sulfuoxide.
3Percentages based on actual values of TNF-α (pg/mL) and NO (μM), compared to controls, are in parentheses.
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three compounds inhibited TNF-α secretion and nitric
oxide (NO) production by LPS-stimulated RAW 264.7
cells, and also inhibited expression of TNF-α, IL-1β, IL-
6, and iNOS genes in LPS-stimulated RAW 264.7 cells
and LPS-stimulated thioglycolate-elicited peritoneal
macrophages derived from both C57BL/6 and BALB/c
mice. Finally, we provided a mechanistic explanation for
these findings, as all three compounds inhibited NF-κB
activation in LPS-stimulated HEK293T cells. NF-κB
enhances transcription of TNF-α, IL-1β, IL-6, and iNOS
genes by binding to promoter sites, so the capacity of
resveratrol, pterostilbene and morin hydrate to inhibit
NF-κB activation would be expected to suppress tran-
scription of these genes in response to LPS stimulation
[26].
As described previously, polyphenols and δ-tocotrienol
act as proteasome inhibitors and thus inhibit inflamma-
tion [5]. Proteasome inhibitors can exert their effects by
impacting transcription factors such as NF-κB, thereby
altering gene expression levels, and by altering the deg-
radation of ubiquitinated proteins targeted for proces-
sing by the proteasome [24]. Therefore, compounds that
target the proteasome affect inflammatory processes andseveral other biological functions. To the best of our
knowledge, this is the first report demonstrating that
resveratrol acts as a proteasome inhibitor, thereby sug-
gesting a plausible mechanism by which resveratrol acts
as an anti-inflammatory compound. We recently
reported that increased NO levels, associated with age-
ing, may be attributable to increased degradation of IκB
by ageing proteasomes, resulting in enhanced NF-κB ac-
tivation [27]. We further demonstrated that these effects
could be reversed by a variety of proteasome inhibitors
[27].
Results of the current study are consistent with our
previous studies of quercetin and δ-tocotrienol, which
are common, naturally-occurring compounds that are
commercially available as dietary supplements. We pre-
viously reported that proteasome inhibition by quercetin
and δ-tocotrienol resulted in decreased proteolytic deg-
radation of P-IκB which, in turn, decreased translocation
of activated NF-κB to the nucleus, and depressed tran-
scription of TNF-α and iNOS genes [5]. We also
reported: 1) that quercetin and δ-tocotrienol inhibited
secretion of TNF-α and NO production by LPS-
stimulated murine macrophages in vitro [5]; 2) that
macrophages from mice fed diets supplemented with
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with decreased levels of mRNA for TNF-α and iNOS
genes, and decreased secretion of TNF-α and NO pro-
duction [23], and; 3) that serum TNF-α and NO levels
were reduced in chickens fed diets supplemented with
quercetin, riboflavin, or δ-tocotrienol [6]. In view of evi-
dence linking dysregulated inflammatory responses to a
variety of age-associated diseases (e.g. cancer, cardiovascular
disease, dementia), findings that diet supplementation with
quercetin, riboflavin, or δ-tocotrienol suppressed inflamma-
tory responses in mice and chickens [6,27], raised the pro-
spect that diet supplementation with comparable agents
could have beneficial health effects in ageing humans [28].
Resveratrol and pterostilbene are present in grapes,
blueberries, and red wine, and have been implicated as
contributing factors to the lower incidence of cardiovas-
cular disease in the French population despite their rela-
tively high dietary fat intake [8-10]. Morin hydrate,
which is an isoflavanoid found in tea leaves, has been
shown to be an effective hypocholesterolemic agent [12].
In view of our findings described in the previous para-
graph, we wanted to determine whether resveratrol,
pterostilbene, and morin hydrate would also inhibit pro-
teasome enzymatic activity and have anti-inflammatory
effects comparable to quercetin and δ-tocotrienol. Our
results indicated that resveratrol and pterostilbene were
particularly potent proteasome inhibitors and anti-
inflammatory agents, producing levels of inhibition that
were at least comparable to, and often exceeding, that of
the positive control (quercetin). Consequently, it appears
likely that the beneficial nutritional affects of resveratrol
and pterostilbene are due, at least in part, to their ability
to inhibit NF-κB activation by the proteasome, thereby
suppressing activation of pro-inflammatory cytokines
and iNOS genes, resulting in decreased production of
TNF-α, IL-1β, IL-6, and NO, in response to inflamma-
tory stimuli.
Our current mechanistic findings are consistent with a
recent report indicating that resveratrol modulates the
stimulatory effects of TLR3 and TLR4, but not TLR2 or
TLR9, ligands by suppressing NF-κB activation and
cyclooxygenase-2 expression [29]. The suppressive effect
of resveratrol appeared to be dependent upon Toll/IL-
1R domain-containing adapter inducing IFN-β (TRIF)
signaling pathways, as suppression was abolished in
TRIF, but not MyD88 deficient mouse cells [29]. Our
previous report, that proteasomes regulate TLR4
dependent inflammatory responses by affecting the
TRIF/TRAM pathway, are entirely consistent with these
findings [23]. These collective results indicating that
dietary phytochemicals, such as trans-resveratrol, can
modulate TLR-derived signaling, inflammatory target
gene expression, and inflammatory cytokine and NO
production, strongly suggest that these compounds canalter susceptibility to microbial infection and chronic in-
flammatory diseases [29].Conclusions
trans-Resveratrol, pterostilbene and morin hydrate inhibit
the proteasome’s protease enzymatic activity, as well as
the capacity of macrophages to produce inflammatory
cytokines and NO in response to LPS stimulation. All
three compounds inhibited chymotrypsin-like, trypsin-
like, and post-glutamase proteasome enzymatic activity of
cultured RAW 264.7 macrophage like cells. All three com-
pounds inhibited production of nitric oxide (NO) and se-
cretion of TNF-α by LPS-stimulated RAW 264.7 cells, and
also inhibited expression of TNF-α, IL-1β, IL-6, and iNOS
genes by LPS-stimulated RAW 264.7 cells and LPS-
stimulated peritoneal macrophages from both C57BL/6
and BALB/c mice. NF-κB activation in LPS-stimulated
HEK293T cells was also inhibited by resveratrol, pterostil-
bene and morin hydrate, providing a likely mechanism by
which these proteasome inhibitors suppress inflammatory
responses. It appears likely that the beneficial nutritional
effects of resveratrol, pterostilbene, and morin hydrate as
anti-inflammatory and anti-carcinogenic agents are due, at
least in part, to their ability to inhibit NF-κB activation by
the proteasome, thereby suppressing activation of pro-
inflammatory cytokines and iNOS genes, resulting in
decreased production of TNF-α, IL-1β, IL6, and NO, in
response to inflammatory stimuli.
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